Ketogenic diet: a nutritional protocol for a non-pharmacological treatment of Alzheimer’s disease

Mariangela Corsi 1 - Tania Di Raimo 1 - Alessandro Pinto 2 - Cherubino Di Lorenzo 1 - Andrea Fuso 3

1 Dipartimento di Scienze e Biotecnologie Medico Chirurgiche, Sapienza Università di Roma, Latina, Italia - 2 Dipartimento di Medicina Sperimentale, Sapienza Università di Roma, Roma, Italia - 3 Dipartimento di Psicologia, Sezione di Neuroscienze, Sapienza Università di Roma, Roma, Italia

Alzheimer’s disease (AD) is a progressively worsening disease that affects specific brain areas involved in spatial memory, short-term memory and has a negative impact on the individual, limiting his ability of independent life. AD remains asymptomatic for a considerable time before cognitive decline becomes clinically evident. For this reason, the establishment of appropriate nutritional protocols, in the early stage, may be more effective than any drug treatments in the fight against this disease. Ketogenic Diet (KD) is a diet high in fat, adequate-proteins and low carbohydrates producing ketone bodies (KBs) (alternative energy source to glucose for the brain). Nowadays, relations between KBs and cerebral Aβ accumulation are not clear. Most studies focus on the neuronal component and forget the vascular component of AD represented by the brain-blood barrier (BBB), located at the cerebral microvessels level. Consequently, it seems essential to focus on the BBB physiology, and in particular on the BBB’s functions of the receptors/transporters and enzymes involved in Aβ peptide transport and metabolism, to better understand the influence of a KD on the onset and the evolution of this disease. For 4 weeks, Wild type mice (129SV) were maintained on KD and Control Diet (CD). Glucose and Beta-hydroxybutyrate (BHB) levels were assessed in blood sample. Microvessel fractions were isolated from total brain and qPCR analyses were performed to study expression of transporters, receptors and enzymes involved in amyloid transport and metabolism at the BBB level. KD fed animals showed increased levels of BHB which was accompanied by an increased expression of Monocarboxylate Transporters 1 (MCT1) and Glucose transporter 1 (GLUT1) at the BBB level. There were not changes in the level of Glucose and body weight in these mice. In addition we observed modifications in the expression of some transporters involved in Aβ exchanges such as Low density lipoprotein receptor-related protein 1 (LRP1) and Multidrug resistance-associated protein 1 (MRP1). The expression of Aβ synthesis enzymes remains unchanged, instead an increase for the Aβ degradation enzyme Endothelin Converting Enzyme 1 (ECE1) was observed. These preliminary results show that dietary factors and in particular KD can modulate the expression of some actors implicated in brain Aβ metabolism at the BBB level.

Keywords
Alzheimer’s disease; brain-blood barrier; ketogenic diet.